AI with intent: How Inizio is redefining pharma through precision and partnership
October 29, 2025 | Intelligent Commercialization
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the future of Intelligent Commercialization™.
Empowering human insight at Fierce Pharma Week
This year’s Fierce Pharma Week brought together the leading voices shaping the future of pharmaceutical communications, strategy, and innovation. At Inizio, we had a front-row seat through the contributions of experts, who showcased how we’re combining human expertise with AI to deliver precision, credibility, and measurable impact.
Across every discussion our experts took part in, one theme stood out: AI delivers its greatest value when guided by intent. From elevating scientific storytelling to advancing field medical enablement and enabling data-driven decision-making, our teams demonstrated how purposeful integration of AI is transforming how pharma connects, learns, and leads.
Here’s how our experts brought that vision to life at Fierce Pharma Week through connected insight, practical innovation, and partnership that drives real-world change.
Engineering credibility in an AI-powered world
In the session “From earned to engineered,” Inizio Evoke’s Will Reese, Theresa Dolge, and Kelly Cusumano urged pharma communicators to rethink visibility in an AI-shaped world.
They discussed the rise of “thin” versus “thick” content, concise, discoverable insights that feed AI models versus deeply sourced narratives that build authority. The strongest brands balance both, ensuring that what AI learns is accurate, credible, and humanly resonant.
As Will noted, “AI rewards content that’s structured, traceable, and solution-oriented.” The key is designing material that both humans and machines can trust, because what’s visible shapes what’s believed.
Explore the full talk delivered by Inizio Evoke here.
Building real capability with real impact
AI delivers the most value when guided by experts who use it with purpose.
Inizio Medical’s Kelly Malloy, SVP of Customer Engagement for AI and Augmented Intelligence, brought this to life during her talk, “The business case for next-gen field medical enablement,” alongside a panel of industry leaders:
- Tiffanie Stewart, PhD, Senior Director, MSLs, Inizio Engage
- Donnie Wooten, Jr., PharmD, Senior Director, Global Medical Capabilities – Oncology, AstraZeneca
- Michael Kahn, formerly Senior Director, Medical Affairs Operations Leader, Spark Therapeutics
Using tools like MSL Interact, teams can rehearse realistic HCP conversations in a safe, simulated environment. It’s a powerful example of using AI to enhance human skills like empathy, curiosity, and dialogue, rather than aiming to replace them. The panel highlighted the value of adaptive, continuous learning along with a “Four Ps” model: prepare, practice, perform, pivot.
“Generative AI is an accelerant, not a shortcut,” Kelly reminded the audience. “When used deliberately, it bridges science and storytelling- helping field teams communicate more clearly and confidently in the moments that matter most.”
Watch the full talk delivered by Inizio Medical here.
Transforming medical affairs with data and AI
Inizio Advisory’s session, “Precision Medical Affairs in action,” led by Lori Klein, Partner, Medical Affairs Practice Lead, brought together expert insights from:
- Nikheel Kolatkar, VP, US Medical, Genentech
- Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
They described how precision Medical Affairs moves from reactive to predictive by using AI-driven analytics to uncover care gaps, localize insights, and personalize scientific engagement, connecting data across functions to create continuous feedback loops, and equip teams to partner confidently with AI.
As Lori summarized, “When you integrate human and machine intelligence, you don’t just find new insights – you create new impact.”
Watch Inizio Advisory’s Fierce Pharma Week session here.
Precision launch: aligning data, strategy, and purpose
In their second session, “Precision launch: Integrating data and AI to power commercial and medical strategy,” Inizio Advisory’s Jo-Ann Saitta, Partner, Global Data Strategy, and Lori Klein, spotlighted the value of data unity and strategic alignment.
Through centralized, compliant products like ClarityNav, part of the Navigator AI™ pharma teams can align next-best actions, understand the voice of the customer, and orchestrate personalized engagements. When medical and commercial teams operate from a single, trusted source of truth, every insight becomes actionable, and every action measurable.
This is what modern launch excellence looks like: predictive, connected, and powered by purpose.
Watch Inizio Advisory’s second Fierce Pharma Week session here.
Innovation rooted in the human equation
Every session echoed one essential truth: AI is only as valuable as the people guiding it. Whether in content, training, or analytics, Inizio’s approach to innovation is grounded in the belief that technology should elevate human creativity rather than eclipse it.
We’re building systems that help decision-makers within healthcare and pharma:
- See more clearly
- Decide more precisely
- Act with greater purpose
Because empathy, curiosity, and expertise, not algorithms, sustain trust in healthcare.
From insight to impact with Intelligent Commercialization™
Fierce Pharma Week reinforced our mission: to lead the future of Intelligent Commercialization™ – where human insight, data, and AI converge to deliver clarity, speed and measurable impact.
- Through strategic intelligence, Navigator AI™ enables faster, smarter portfolio and investment decisions, sharpens strategy, strengthens field execution, and accelerates launches.
- Through medical intelligence, iON.AI™ converts scientific evidence into actionable insights that enhance the influence and effectiveness of Medical Affairs execution.
- Through commercial intelligence, Cognitev™ translates primary generated behavioral data into activation – fueling omnichannel engagement, optimizing field force strategy, and aligning tactics across the lifecycle.
Together, we help the industry move beyond insight to action through accelerating launches, sharpening strategies, and driving real-world impact across the full lifecycle of commercialization.
Ready to unlock the power of Intelligent Commercialization™ across your organization?
Let’s talk about how using AI with intent can elevate your strategy, accelerate impact, and drive smarter engagement across the product lifecycle. Connect with our experts here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Webcast
Monitoring the impact of COVID-19 on the market access landscape
Live webinar from Singapore
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Guide
UX research
Article: Why pharma must trust the science of behaviour
In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...
Case study
Using qualitative conjoint to assess willingness-to-pay
Consumer health specialist joins Research Partnership Inc
Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.
Article: What’s next? How behavioural science can support pharma’s future
Dan Coffin, Director explains why now is an opportune time for pharma marketers to embrace behavioural science. Read his latest article for PME Magazine.https://bit.ly/31ef6rh
Video: UX/ Experience design research
Director and UX expert Liza Pliss discusses Research Partnership's approach to user experience research and shares an example of a project where using design thinking led to an agile approach...
White paper: The impact of COVID-19 on chronic disease management
Therapy Watch, Research Partnership's syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, Research Partnership share some of the insights and...
Article: Pricing a coronavirus vaccine
Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...